Bone Marrow Aspirate Concentrate for the Treatment of Knee O
Bone marrow aspirate concentrate (BMAC) has emerged as a therapeutic option for symptomatic knee osteoarthritis (OA).
A Study was conducted to systematically review the literature to evaluate the efficacy of isolated BMAC injection in the treatment of OA of the knee joint.

8 studies met the inclusion criteria, including a total of 299 knees with a mean follow-up of 12.9 months.

--Of all patient-reported outcomes assessed across studies, 34 of 36 demonstrated significant improvement from baseline to latest follow-up.

--5 studies evaluating numerical pain scores reported significant improvements in pain level at final follow-up.

In conclusion, at short to midrange follow-up, the BMAC injection is beneficial in relieving pain and patient-reported outcomes in individuals with knee OA. However, in comparison to other biologic therapies routinely utilized in the treatment of OA, such as platelet-rich plasma and microfragmented adipose tissue, or to placebo, BMAC has not shown clinical superiority.